Jared Kaltwasser

Patients who have pulmonary arterial hypertension (PAH) often do not feel better after treatment, even if they meet clinical endpoints for improvement.

The majority of respondents living with generalized myasthenia gravis (MG) were not working, the results showed.

Two studies, one of zanubrutinib alone and one that combined the therapy with tislelizumab, showed promising results in a subset of patients.

Investigators said disease-modifying therapies may change the treatment landscape of sickle cell disease (SCD).

A new small case series finds higher rates of symptom flares in individuals who have muscle-specific tyrosine kinase (MuSK)–positive myasthenia gravis (MG) than previous research.

Focus groups show patients who have sickle cell disease (SCD) like the idea of a digital health app for cognitive behavioral therapy (CBT) that allows them to make meaningful connections with people with shared experiences.

Even after adjusting for other risk factors, patients with COPD were more likely to be readmitted to the hospital with heart failure following an acute myocardial infarction, or heart attack.

Health systems participating in the drug discount program did not have fewer disparities than hospitals not participating.

The patient had hemophilia A, but reported no trauma preceding the hematoma.

The training did not, however, affect postoperative limb skeletal muscle weakness or exercise capacity.

Just 29% of patients listed a treatment-response goal among their top personal goals.

No benefit was found in low-risk patients who underwent pelvic lymph node dissection (PLND).

The results of a new focus group offer insights on how and when people with rare diseases are willing to share their personal health information.

The findings support policies urging vaccination of individuals who have myasthenia gravis (MG).

Treatment options have improved care, but also increased the need for patient education.

About a quarter of joints examined had at least 1 joint bleed.

Investigators said data show social factors are intertwined with health outcomes.

A patient’s inability to count while holding their breath can be an indication of respiratory distress in myasthenia gravis.

Gene therapies could have a major impact, although the cost and complexities could inhibit their wide rollout, study authors said.

However, the patients also said they worried about insufficient care coordination between specialists and other care providers.

Investigators found patients with acute coronary syndrome were 3 times more likely to die in the hospital.

People with myasthenia gravis (MG) had a higher risk of hospitalization for COVID-19 compared to the general population and a control group of people with rheumatoid arthritis (RA).

Older people with psoriasis had a roughly 50% higher risk of being diagnosed with a malignancy, investigators found.

The projected cost reductions held both for patients switching from a different extended-half-life product and for patients switching from a standard-half-life product.

Ten-year mean costs associated with psoriasis-related health care visits were 10 times higher for patients with generalized pustular psoriasis (GPP).

Clinicians treating patients with polycythemia vera are too reliant upon phlebotomy, data suggest.

The data show how disease-modifying therapies are changing outcomes for children with spinal muscular atrophy (SMA), a rare neuromuscular disease.

A new case series highlights characteristics and challenges of this subgroup of patients with myasthenia gravis (MG).

Most patients with chronic thromboembolic pulmonary hypertension (CTEPH) said they can go about their daily activities without restriction, the authors found, because of gains in functional status and quality of life (QOL).

A review of cases involving Jehovah’s Witnesses found many modalities can be successfully deployed to treat thrombotic thrombocytopenic purpura (TTP).